Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.045 CAD | 0.00% | 0.00% | +80.00% |
Valuation
Fiscal Period: June | 2023 |
---|---|
Capitalization 1 | - |
Enterprise Value (EV) 1 | - |
P/E ratio | -2.04 x |
Yield | - |
Capitalization / Revenue | - |
EV / Revenue | - |
EV / EBITDA | - |
EV / FCF | - |
FCF Yield | - |
Price to Book | -1.97 x |
Nbr of stocks (in thousands) | - |
Reference price 2 | 0.0794 |
Announcement Date | 02/11/23 |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2022 | 2023 |
---|---|---|
Net sales | - | - |
EBITDA 1 | -5.361 | - |
EBIT 1 | -5.4 | -3.22 |
Operating Margin | - | - |
Earnings before Tax (EBT) 1 | -7.475 | -4.287 |
Net income 1 | -7.475 | -4.287 |
Net margin | - | - |
EPS 2 | -0.1399 | -0.0389 |
Free Cash Flow | - | -1.395 |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 02/11/23 | 02/11/23 |
Balance Sheet Analysis
Fiscal Period: June | 2022 | 2023 |
---|---|---|
Net Debt 1 | 3.15 | 4.64 |
Net Cash position 1 | - | - |
Leverage (Debt/EBITDA) | -0.5873 x | - |
Free Cash Flow | - | -1.39 |
ROE (net income / shareholders' equity) | - | 88.9% |
ROA (Net income/ Total Assets) | - | -176% |
Assets 1 | - | 2.437 |
Book Value Per Share 2 | -0.0800 | -0.0400 |
Cash Flow per Share 2 | 0.0200 | 0 |
Capex | - | - |
Capex / Sales | - | - |
Announcement Date | 02/11/23 | 02/11/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+80.00% | 4.37M | |
+43.64% | 749B | |
+39.42% | 605B | |
-6.58% | 351B | |
+19.72% | 328B | |
+8.78% | 292B | |
+11.92% | 216B | |
-2.62% | 214B | |
+0.03% | 167B | |
+6.13% | 165B |
- Stock Market
- Equities
- MBIO Stock
- Financials MindBio Therapeutics Corp.